We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GW Pharmaceuticals has announced preliminary results from two Phase III studies of Sativex, its cannabinoid spray medicine, in peripheral neuropathic pain.
SemBioSys Genetics announced that its proprietary plant-produced insulin has been demonstrated in animal models to be chemically, structurally and functionally equivalent to U.S. pharma-grade human insulin.
ReNeuron has announced an update on the status of its recently filed investigational new drug (IND) application to begin a Phase I clinical study of its ReN001 stem cell therapy for stroke.
Speedel has begun a Phase I trial of SPP1148, its most promising compound from a new series of renin inhibitors for the treatment of hypertension and related disease.
Xytis announced it has received approval to begin a Phase II clinical trial with Anatibant for the treatment of traumatic brain injury (TBI) in the United Kingdom and South Africa, and enrollment of the first patient is expected to happen this month.
ThromboGenics has initiated a Phase IIb clinical trial of microplasmin in vitrectomy, or surgical removal of the vitreous from the eye, in the United States.
Ziopharm Oncology announced that ZIO-101, a novel, proprietary organic arsenic, has been administered to the first patient in a Phase II trial in blood and bone marrow cancers.